View Item 

Show simple item record

IMP-3 expression in melanocytic lesions
dc.contributor.authorYu, Liminen_US
dc.contributor.authorXu, Haodongen_US
dc.contributor.authorWasco, Matthew J.en_US
dc.contributor.authorBourne, Patricia A.en_US
dc.contributor.authorMa, Lingleien_US
dc.date.accessioned2010-06-01T22:32:03Z
dc.date.available2010-06-01T22:32:03Z
dc.date.issued2010-03en_US
dc.identifier.citationYu, Limin; Xu, Haodong; Wasco, Matthew J.; Bourne, Patricia A.; Ma, Linglei (2010). "IMP-3 expression in melanocytic lesions." Journal of Cutaneous Pathology 37(3): 316-322. <http://hdl.handle.net/2027.42/75517>en_US
dc.identifier.issn0303-6987en_US
dc.identifier.issn1600-0560en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75517
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19788446&dopt=citationen_US
dc.format.extent688687 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rightsCopyright © 2010 John Wiley & Sons A/Sen_US
dc.titleIMP-3 expression in melanocytic lesionsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelDermatologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Dermatology, University of Michigan Medical Center, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherDepartment of Pathologyen_US
dc.contributor.affiliationotherDepartment of Pathology, University of Rochester Medical Center, Rochester, NY, USAen_US
dc.identifier.pmid19788446en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75517/1/j.1600-0560.2009.01428.x.pdf
dc.identifier.doi10.1111/j.1600-0560.2009.01428.xen_US
dc.identifier.sourceJournal of Cutaneous Pathologyen_US
dc.identifier.citedreferenceRies LMD, Krapcho M, Stinchcomb DG, et al. SEER cancer statistics review, 1975–2005. Bethesda, MD: National Cancer Institute, 2005.en_US
dc.identifier.citedreferenceCorona R, Mele A, Amini M, et al. Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol 1996; 14: 1218.en_US
dc.identifier.citedreferenceNielsen FC, Nielsen J, Christiansen J. A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking. Scand J Clin Lab Invest Suppl 2001; 234: 93.en_US
dc.identifier.citedreferenceMueller-Pillasch F, Pohl B, Wilda M, et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 1999; 88: 95.en_US
dc.identifier.citedreferenceJiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006; 7: 556.en_US
dc.identifier.citedreferenceLi C, Rock KL, Woda BA, Jiang Z, Fraire AE, Dresser K. IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol 2007; 20: 242.en_US
dc.identifier.citedreferenceSitnikova L, Mendese G, Liu Q, et al. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res 2008; 14: 1701.en_US
dc.identifier.citedreferenceLiao B, Hu Y, Herrick DJ, Brewer G. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 2005; 280: 18517.en_US
dc.identifier.citedreferenceWang T, Fan L, Watanabe Y, et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer 2003; 88: 887.en_US
dc.identifier.citedreferencePryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA, Xu H. IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol 2008; 21: 431.en_US
dc.identifier.citedreferenceThomas AJ, Erickson CA. The making of a melanocyte: the specification of melanoblasts from the neural crest. Pigment Cell Melanoma Res 2008; 21: 598.en_US
dc.identifier.citedreferenceGreene FLPD, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M, eds. AJCC cancer staging manual, 6th ed. New York: Springer, 2002.en_US
dc.identifier.citedreferenceJiang Z, Lohse CM, Chu PG, et al. Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer 2008; 112: 2676.en_US
dc.identifier.citedreferenceBusam KJ. Cutaneous desmoplastic melanoma. Adv Anat Pathol 2005; 12: 92.en_US
dc.identifier.citedreferenceQuinn MJ, Crotty KA, Thompson JF, Coates AS, O’Brien CJ, McCarthy WH. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer 1998; 83: 1128.en_US
dc.identifier.citedreferenceSmithers BM, McLeod GR, Little JH. Desmoplastic, neural transforming and neurotropic melanoma: a review of 45 cases. Aust N Z J Surg 1990; 60: 967.en_US
dc.identifier.citedreferenceJain S, Allen PW. Desmoplastic malignant melanoma and its variants. A study of 45 cases. Am J Surg Pathol 1989; 13: 358.en_US
dc.identifier.citedreferenceWasco MJ, Pu RT, Yu L, Su L, Ma L. Expression of gamma-H2AX in melanocytic lesions. Hum Pathol 2008; 39: 1614.en_US
dc.identifier.citedreferenceBarnhill RL. The Spitzoid lesion: rethinking Spitz tumors, atypical variants, ‘Spitzoid melanoma’ and risk assessment. Mod Pathol 2006; 19: S21.en_US
dc.identifier.citedreferenceBarnhill RL, Argenyi ZB, From L, et al. Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol 1999; 30: 513.en_US
dc.identifier.citedreferenceFarmer ER, Gonin R, Hanna MP. Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol 1996; 27: 528.en_US
dc.identifier.citedreferenceLudgate MW, Fullen DR, Lee J, et al. The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution. Cancer 2009; 115: 631.en_US
dc.identifier.citedreferenceKapur P, Selim MA, Roy LC, Yegappan M, Weinberg AG, Hoang MP. Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis. Mod Pathol 2005; 18: 197.en_US
dc.identifier.citedreferenceKanter-Lewensohn L, Hedblad MA, Wejde J, Larsson O. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas. Mod Pathol 1997; 10: 917.en_US
dc.identifier.citedreferenceBastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 1998; 58: 2170.en_US
dc.identifier.citedreferenceHarvell JD, Kohler S, Zhu S, Hernandez-Boussard T, Pollack JR, van de Rijn M. High-resolution array-based comparative genomic hybridization for distinguishing paraffin-embedded Spitz nevi and melanomas. Diagn Mol Pathol 2004; 13: 22.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1600-0560.2009.01428.x.pdf
Size:
672.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.